Blog Archives

Risk of Bullous Pemphigoid with Type 2 Diabetes Drugs

August 12, 2018 – Findings from a retrospective case-control study were published online August 8, 2018, in JAMA Dermatology indicate that the use of certain dipeptidyl peptidase 4 (DPP-4) inhibitor drugs are associated with a small but significantly elevated risk for developing bullous pemphigoid,

Read more ›

Tags: , , , , , , , , , , , , ,

Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class, including Saxagliptin (Onglyza),

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors?

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) may be associated with rhabdomyolysis,

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

Bristol-Myers gets approval for its diabetes drug Saxagliptin [Onglyza] in the European Union (EU)

October 14, 2009 – On October 5, 2009, drug maker Bristol-Myers Squibb Co. announced that its new diabetes drug, Saxagliptin [Onglyza], has been approved for sale in the European Union’s (EU) 27 countries.

Saxagliptin [Onglyza] is the first diabetes drug to be launched in Europe by a partnership of New York-based Bristol-Myers and British drugmaker AstraZeneca PLC to develop drugs for type 2 diabetes.

Read more ›

Tags: , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • When macrophages are deprived of oxygen May 24, 2019
    Infected tissue has a low concentration of oxygen. The body's standard immune mechanisms, which rely on oxygen, can then only function to a limited extent. How does the immune system nevertheless manage to control bacteria under such conditions? Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Regensburg discovered that fewer metabolites are produced in the citric […]
  • Science Snapshots -- May 2019 May 24, 2019
    Researchers at Berkeley Lab's Molecular Foundry have predicted fascinating new properties of lithium; a powerful combination of experiment and theory has revealed atomic-level details about how silver helps transform carbon dioxide gas into a reusable form; new study reports the first comprehensive, highly coordinated effort to examine the global diversity and biogeography of activated sludge […]
  • Information and language in news impact prejudice against minorities May 23, 2019
    Researchers at the Institute of Psychology show how news about immigrants and language describing immigrants shape prejudice against immigrants and other social minorities, as part of the project 'Immigrants in the Media.' For instance, nouns used for describing the ethnicity of immigrants enhance prejudice against immigrants more than adjectives.
  • Artificial atomic scale materials: Discovering how electrons fatten! May 23, 2019
    A single and isolated electron has a clear electrical charge, magnetic moment and mass, and its free movement can be precisely predicted. Spanish scientists fabricated a nanoscale artificial material manipulating atoms one after the other and discovered that electrons around are very heavier. Heavy electrons are promising particles which endow of new functionalities to novel […]
  • Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear May 23, 2019
    Meaningful studies are lacking for certain patient groups. Disease-specific registries could help close the data gap.
Top